These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 11674325)

  • 1. Selective Inhibition of Type II Dehydroquinases.
    Frederickson M; Parker EJ; Hawkins AR; Coggins JR; Abell C
    J Org Chem; 1999 Apr; 64(8):2612-2613. PubMed ID: 11674325
    [No Abstract]   [Full Text] [Related]  

  • 2. (1R,4S,5R)-3-Fluoro-1,4,5-trihydroxy-2-cyclohexene-1-carboxylic acid: the fluoro analogue of the enolate intermediate in the reaction catalyzed by type II dehydroquinases.
    Frederickson M; Roszak AW; Coggins JR; Lapthorn AJ; Abell C
    Org Biomol Chem; 2004 Jun; 2(11):1592-6. PubMed ID: 15162210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of electrospray mass spectrometry to identify an essential arginine residue in type II dehydroquinases.
    Krell T; Pitt AR; Coggins JR
    FEBS Lett; 1995 Feb; 360(1):93-6. PubMed ID: 7875309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specificity of substrate recognition by type II dehydroquinases as revealed by binding of polyanions.
    Evans LD; Roszak AW; Noble LJ; Robinson DA; Chalk PA; Matthews JL; Coggins JR; Price NC; Lapthorn AJ
    FEBS Lett; 2002 Oct; 530(1-3):24-30. PubMed ID: 12387860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence from kinetic isotope studies for an enolate intermediate in the mechanism of type II dehydroquinases.
    Harris JM; Gonzalez-Bello C; Kleanthous C; Hawkins AR; Coggins JR; Abell C
    Biochem J; 1996 Oct; 319 ( Pt 2)(Pt 2):333-6. PubMed ID: 8912664
    [No Abstract]   [Full Text] [Related]  

  • 6. Conformational changes and the role of metals in the mechanism of type II dehydroquinase from Aspergillus nidulans.
    Bottomley JR; Hawkins AR; Kleanthous C
    Biochem J; 1996 Oct; 319 ( Pt 1)(Pt 1):269-78. PubMed ID: 8870678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and evaluation of potent ene-yne inhibitors of type II dehydroquinases as tuberculosis drug leads.
    Tran AT; Cergol KM; West NP; Randall EJ; Britton WJ; Bokhari SA; Ibrahim M; Lapthorn AJ; Payne RJ
    ChemMedChem; 2011 Feb; 6(2):262-5. PubMed ID: 21275049
    [No Abstract]   [Full Text] [Related]  

  • 8. Cloning, sequencing, expression, purification and preliminary characterization of a type II dehydroquinase from Helicobacter pylori.
    Bottomley JR; Clayton CL; Chalk PA; Kleanthous C
    Biochem J; 1996 Oct; 319 ( Pt 2)(Pt 2):559-65. PubMed ID: 8912695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and structural studies on potent biaryl inhibitors of type II dehydroquinases.
    Payne RJ; Riboldi-Tunnicliffe A; Kerbarh O; Abell AD; Lapthorn AJ; Abell C
    ChemMedChem; 2007 Jul; 2(7):1010-3. PubMed ID: 17487901
    [No Abstract]   [Full Text] [Related]  

  • 10. The folding and assembly of the dodecameric type II dehydroquinases.
    Price NC; Boam DJ; Kelly SM; Duncan D; Krell T; Gourley DG; Coggins JR; Virden R; Hawkins AR
    Biochem J; 1999 Feb; 338 ( Pt 1)(Pt 1):195-202. PubMed ID: 9931316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rational design, synthesis, and evaluation of nanomolar type II dehydroquinase inhibitors.
    Payne RJ; Peyrot F; Kerbarh O; Abell AD; Abell C
    ChemMedChem; 2007 Jul; 2(7):1015-29. PubMed ID: 17487900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inducible overproduction of the Aspergillus nidulans pentafunctional AROM protein and the type-I and -II 3-dehydroquinases from Salmonella typhi and Mycobacterium tuberculosis.
    Moore JD; Lamb HK; Garbe T; Servos S; Dougan G; Charles IG; Hawkins AR
    Biochem J; 1992 Oct; 287 ( Pt 1)(Pt 1):173-81. PubMed ID: 1329726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The occurrence of two dehydroquinases in Neurospora crassa, one constitutive and one inducible.
    Giles NH; Partridge CW; Ahmed SI; Case ME
    Proc Natl Acad Sci U S A; 1967 Nov; 58(5):1930-7. PubMed ID: 4966264
    [No Abstract]   [Full Text] [Related]  

  • 14. Mechanistic insight into the reaction catalysed by bacterial type II dehydroquinases.
    Coderch C; Lence E; Peón A; Lamb H; Hawkins AR; Gago F; González-Bello C
    Biochem J; 2014 Mar; 458(3):547-57. PubMed ID: 24392963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress in type II dehydroquinase inhibitors: from concept to practice.
    González-Bello C; Castedo L
    Med Res Rev; 2007 Mar; 27(2):177-208. PubMed ID: 17004270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of the active-site lysine residues of two biosynthetic 3-dehydroquinases.
    Chaudhuri S; Duncan K; Graham LD; Coggins JR
    Biochem J; 1991 Apr; 275 ( Pt 1)(Pt 1):1-6. PubMed ID: 1826831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure of the Aspergillus nidulans qut repressor-encoding gene: implications for the regulation of transcription initiation.
    Hawkins AR; Lamb HK; Roberts CF
    Gene; 1992 Jan; 110(1):109-14. PubMed ID: 1544567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The characterisation of the shikimate pathway enzyme dehydroquinase from Pisum sativum.
    Deka RK; Anton IA; Dunbar B; Coggins JR
    FEBS Lett; 1994 Aug; 349(3):397-402. PubMed ID: 8050603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effects of non-selective and selective phosphodiesterase inhibitors on human eosinophil functions.
    Hatzelmann A; Tenor H; Schudt C
    Br J Pharmacol; 1995 Feb; 114(4):821-31. PubMed ID: 7539697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Control of metabolic flux through the quinate pathway in Aspergillus nidulans.
    Wheeler KA; Lamb HK; Hawkins AR
    Biochem J; 1996 Apr; 315 ( Pt 1)(Pt 1):195-205. PubMed ID: 8670107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.